Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 4/20 | 0.41 |
| ▸ | KDR | P35968 | 3/20 | 0.36 |
| ▸ | PRKACA | P17612 | 2/20 | 0.36 |
| ▸ | CDK8 | P49336 | 2/20 | 0.36 |
| ▸ | CDK9 | P50750 | 2/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.35 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.35 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | LTK | P29376 | 1/20 | 0.34 |
| ▸ | GRK5 | P34947 | 1/20 | 0.34 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6837080 | 0.79 | PRKACA (0.36) | KDRPRKACACDK8CDK9ROCK1 | |
| SCHEMBL369723 | 0.71 | PRKACA (0.34) | KDRPRKACACDK8CDK9ROCK1 | |
| SCHEMBL12944579 | 0.69 | ELANE (0.36) | ELANEMAP2K1ALDH1A1MAPTTHRB | |
| SCHEMBL5944129 | 0.69 | — | — | |
| SCHEMBL6837091 | 0.68 | ESR1 (0.32) | ESR1ESR2 | |
| SCHEMBL6333956 | 0.66 | CCNA2 (0.41) | CCNA2CDK2CCNA1GRM4ALDH1A1 | |
| SCHEMBL1395016 | 0.66 | GRM4 (0.41) | ELANECCNA2CDK2CCNA1GRM4 | |
| SCHEMBL29590771 | 0.66 | GRM4 (0.38) | CCNA2CDK2CCNA1GRM4ALDH1A1 | |
| SCHEMBL6476656 | 0.66 | GRM4 (0.38) | CCNA2CDK2CCNA1GRM4ALDH1A1 | |
| SCHEMBL22216418 | 0.65 | ALDH1A1 (0.46) | GRM4DRD2ALDH1A1HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8697744-B2 | Substituted 5,6-dihydro-4H-thiazolo[4,5-E]indazoles and their use as positive allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMA S.A. (CH) | 2014-04-15 | — | — | US | disclosed |
| EP-2408762-A1 | HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF | SANOFI (FR) | 2012-01-25 | — | — | EP | disclosed |
| WO-2012006760-A1 | TRICYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012008999-A2 | TRICYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2012-01-19 | — | — | WO | disclosed |
| US-20120010241-A1 | HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF | SANOFI (FR) | 2012-01-12 | — | — | US | disclosed |
| US-20110319425-A1 | HETEROTRICYCLIC COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2011-12-29 | — | — | US | disclosed |
| EP-2382219-A1 | HETEROTRICYCLIC COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX Pharma S.A. (CH) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010106290-A1 | HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010079238-A1 | HETEROTRICYCLIC COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA S.A. (CH) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010241-A1 | HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF | HSP90AB2P, HSP90AB1, HSP90AA1 | ELANE 3276/4885KDR 2395/4885PRKACA 2983/4885 |
| US-20110319425-A1 | HETEROTRICYCLIC COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM1, GRM4, GRM2 | ELANE 4784/4885KDR 4110/4885PRKACA 2970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.